US biosimilar ‘void’ spells trouble as biologic patent expirations loom, IQVIA report saysnews2025-02-03T20:38:59+00:00February 3rd, 2025|Endpoints News|
Drug prices likely to soar due to Trump tariffs, pharma bodies warnnews2025-02-03T11:57:24+00:00February 3rd, 2025|Endpoints News|
J&J’s Rybrevant gets CHMP backing weeks after FDA rejectionnews2025-02-03T11:55:40+00:00February 3rd, 2025|Endpoints News|
Pfizer says new colorectal cancer data could support full approval of Braftovinews2025-02-03T11:45:24+00:00February 3rd, 2025|Endpoints News|
AbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up Humira’s mantlenews2025-01-31T20:03:04+00:00January 31st, 2025|Endpoints News|
Genentech joins suits against STD clinics over 340B discountsnews2025-01-31T20:00:37+00:00January 31st, 2025|Endpoints News|
England agrees to pay for Vertex’s sickle cell disease gene therapynews2025-01-31T17:22:49+00:00January 31st, 2025|Endpoints News|
AstraZeneca scraps plan to expand UK vaccine sitenews2025-01-31T16:45:15+00:00January 31st, 2025|Endpoints News|
Celltrion looks to buy US facilities to sidestep potential Trump tariffs news2025-01-31T13:38:52+00:00January 31st, 2025|Endpoints News|
AbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 salesnews2025-01-31T12:38:47+00:00January 31st, 2025|Endpoints News|
